|
26 June 2014 |
VEGAS LEX and IMEDA discuss anti-monopoly risk management on medical products marketThe discussion focused on main trends in building effective compliance control systems and anti-monopoly risk management in this segment. VEGAS LEX was represented by partner Alexander Sitnikov and Maria Borzova, Manager of Life Sciences Projects. The participants studied cases to identify the key groups of anti-monopoly risks that are the most critical for the medical products and equipment segment. They analyzed the main indicators that anti-monopoly regulators use to open collusion cases and identified ways to use trading policies as a risk-mitigation tool. VEGAS LEX experts also analyzed the types of practices on this market that anti-monopoly regulators find inappropriate and define as unfair competition. In the course of the discussion the experts also proposed ways to exclude or mitigate some of the risks. Head of VEGAS LEX Commercial Practice also actively participated in the discussion, along with two IMEDA officials, Executive Director Alexandra Tretyakova and Legal Director Mikhail Potapov. Sergei Nikolayev, deputy head of the Federal Anti-Monopoly Service’s department for healthcare and social policy, specially invited to join the workshop, answered the participants’ questions and spoke about some practical aspects of anti-monopoly litigation in the medical products segment. The event was attended by the leaders and legal officials of companies that make medical products and representatives of professional associations. *** For more information on VEGAS LEX’s services in the medical products sphere, go here. |
